Icosavax: AstraZeneca's Icosavax M&A Deal Helps It Stand Out in Multivalent Vaccines Chase
AstraZeneca is acquiring Icosavax, which has technology well-suited for multivalent vaccines. Icosavax's pipeline includes a Phase 3-ready program that protects against two pathogens that cause severe respiratory infections in older adults.
Read full article »
Icosavax is a Washington-based biotechnology company that researches and develops VLP vaccines for the treatment of respiratory diseases.
Read more